Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02808455 · ClinicalTrials.gov registry record · Phase 1
Study to Assess the Relative Bioavailability of Pacritinib Following Oral Administration as Capsule and Solution Formulations in Healthy Subjects
A Phase 1 study, sponsored by CTI BioPharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT02808455: Completed Phase 1 study, sponsored by CTI BioPharma.
NCT02808455 is a Phase 1 study that has completed, run by CTI BioPharma. The registered enrollment target is 12 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02808455, a Phase 1 study, has completed, sponsored by CTI BioPharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
This was a randomized, 2-period, 2-treatment-sequence crossover study to determine the relative bioavailability of pacritinib following administration as a 400 mg oral dose of four 100 mg pacritinib capsules and an 80 mg dose of an oral solution and to characterize the PK and major human metabolites of pacritinib.
Interventions
- DRUG (Treatment A)
- DRUG (Treatment B)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2015-01 |
| Est. Completion | 2015-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02808455
The ClinicalTrials.gov registry entry for NCT02808455 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CTI BioPharma, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which (Treatment A) is the first listed.
NCT02808455 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02808455 about?
NCT02808455 is a clinical study titled "Study to Assess the Relative Bioavailability of Pacritinib Following Oral Administration as Capsule and Solution Formulations in Healthy Subjects". This was a randomized, 2-period, 2-treatment-sequence crossover study to determine the relative bioavailability of pacritinib following administration as a 400 mg oral dose of four 100 mg pacritinib capsules and an 80 mg dose of an oral solution and to characterize the PK and major human metabolites...
What is the current status of trial NCT02808455?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2015-01. Estimated completion is 2015-03.
What interventions are being tested in trial NCT02808455?
The interventions under investigation include: (Treatment A) (DRUG), (Treatment B) (DRUG).
Who is sponsoring clinical trial NCT02808455?
This trial is sponsored by CTI BioPharma, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.